Congress finally receives legislation on FDA
This article was originally published in Clinica
After months of hearings, conferences and reports, legislation on major changes in the FDA drug and device approval process has been introduced to Congress. Presenting the FDA Modernisation Act of 1995 (HR 1742) on June 6th, congressman Ron Wyden told colleagues: "It is crucial ... that the federal regulatory system so integral to the development and commercialisation of new [drugs and medical devices] changes, improves and advances in step with [the] technological revolution" which is now occurring.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.